Evolus (EOLS)

• Market cap: $397M
• 1 day: -3.05%
• 5 days: 3.25%
• 1 month: -15.43%
• 3 months: 16.41%
• 6 months: 29.4%
• Year to date: -10.27%
• 1 year: -34.81%
• 5 years: -44.22%
• 10 years: -47.57%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Employees: 350